$2M Aurobindo Irbesartan Drug Contamination Settlement, Do You Qualify for a Cash Payment? Claim Before June 2

If you bought Aurobindo’s irbesartan blood pressure medication any time since January 2016, you may be entitled to a cash payment from a $2 million class action settlement. The lawsuit claims these pills contained a probable cancer-causing chemical called NDEA. Aurobindo denies any wrongdoing, but has agreed to settle. The deadline to file a claim is June 2, 2026.

Quick Facts

Field	Detail
Settlement Amount	$2,000,000
Claim Deadline	June 2, 2026
Who Qualifies	U.S. residents who paid out of pocket for Aurobindo irbesartan since January 1, 2016
Payout Per Person	$10.71 per 30-day supply purchased (up to $128.52 without proof)
Proof Required	No — for standard claims up to $128.52. Yes — for claims above that amount
Settlement Status	Open for Claims (Preliminary Approval Granted)
Administrator	Postlethwaite & Netterville (Sartan Medication Settlement Administrator)
Official Website	sartanmedicationsettlement.com

Where Things Stand Right Now

• The settlement has received preliminary court approval and is currently open for claims.
• The opt-out and objection deadlines both fall on June 2, 2026 — the same day as the claim filing deadline.
• A Final Approval Hearing is scheduled for June 30, 2026, at 10:00 a.m. at the U.S. District Court for the District of New Jersey. Payments go out after the court grants final approval at that hearing.

What Was Aurobindo’s Irbesartan Accused Of?

Irbesartan is a common prescription medication used to treat high blood pressure (hypertension) and protect the kidneys in people with type 2 diabetes. Millions of Americans take this type of drug daily, often for years at a time.

The lawsuit — filed as part of a larger federal case called In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation (Case No. 1:19-md-02875) — claims that Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., and Aurolife Pharma LLC sold irbesartan pills that contained NDEA (N-Nitrosodiethylamine). NDEA is classified as a probable human carcinogen, meaning it is a chemical that may cause cancer in people who are repeatedly exposed to it.

Plaintiffs allege that Aurobindo violated state consumer protection laws by distributing a medication contaminated with this substance. Aurobindo disputes those claims and denies that the NDEA levels in its pills posed any cancer risk. The court has not decided who is right — both sides agreed to settle to resolve the dispute and avoid a lengthy trial.

Who Can File a Claim?

You may qualify for a payment if you meet all of the following:

• You are an individual living in the United States, its territories, or its possessions.
• You paid out of pocket for retail purchases of Aurobindo irbesartan — this includes copays, coinsurance, or the full retail price. It also covers purchases you made on behalf of a dependent.
• Your purchases occurred between January 1, 2016, and the present.
• Your medication used Aurobindo’s IC Route of Synthesis (IC ROS) for manufacturing the active pharmaceutical ingredient. You can check whether your pills qualify by looking at the National Drug Code (NDC) on your prescription bottle.

Qualifying NDC codes include: 60429-640-90, 60429-641-30, 60429-641-90, 60429-642-30, 60429-642-90, 69367-119-01, 69367-119-03, 69367-120-01, 69367-120-03, 69367-121-01, and 69367-121-03.

You do not qualify if you are a Pharmacy Benefit Manager (PBM), a federal or state government entity, a personal injury plaintiff in the same MDL, or a judge involved in this case.

How Much Money Can You Actually Get?

Your payout depends on how many 30-day supplies of Aurobindo irbesartan you purchased — and whether you have documentation to back up your claim.

Standard claims (no documentation required):

• $10.71 per 30-day supply purchased
• Maximum of $128.52 per person (equivalent to 12 months of supply)

Documented claims (receipts or pharmacy records required):

• If your actual out-of-pocket cost exceeded $10.71 per 30-day supply, you can claim the higher documented amount.
• There is no cap on documented individual claims — you can recover the full amount you actually paid.
• However, total consumer payouts across all claimants cannot exceed 70% of the net settlement fund (after attorneys’ fees, administration costs, and service awards). If total valid claims exceed that cap, all individual payments get reduced proportionally.

Related article: $11.37M Hetero Valsartan Drug Contamination Settlement, Could You Qualify for a Cash Payment? Claim Before June 2, 2026

How the $2 million breaks down:

• Attorneys’ fees: up to $666,667
• Service awards to class representatives: $7,000 total
• Settlement administration costs: TBD
• Consumer payments: remaining balance

If you bought irbesartan for several years and paid standard copays, filing even a basic no-proof claim could put money back in your pocket for something you already spent.

How to File Your Claim (Step by Step)

Estimated time to complete: 5–10 minutes online

Step 1 — Go to the official claim portal at sartanmedicationsettlement.pnclassaction.com

Step 2 — Enter your personal information, including your name, current address, and contact details

Step 3 — Identify the Aurobindo irbesartan you purchased, including NDC codes if available, and the approximate number of 30-day supplies you bought

Step 4 — Choose your claim type: standard (no proof) or documented (with receipts or pharmacy records showing higher out-of-pocket costs)

Step 5 — Upload any supporting documentation if you are filing a documented claim above the $128.52 cap

Step 6 — Submit your claim and save your confirmation number for your records

Prefer to file by mail? Download and print the paper claim form and mail it to:

Sartan Medication Settlement Administrator PO Box 3376 Baton Rouge, LA 70821

Your paper form must be postmarked by June 2, 2026.

Key Deadlines at a Glance

Milestone	Date
Settlement Preliminary Approval	Granted (2026)
Claims Period Opens	April 2026
Claim Filing Deadline	June 2, 2026
Opt-Out (Exclusion) Deadline	June 2, 2026
Objection Deadline	June 2, 2026
Final Approval Hearing	June 30, 2026
Expected Payment Date	After June 30, 2026 (TBD)

Frequently Asked Questions

Do I need a lawyer to file a claim? 

No. You can file your claim directly on the official settlement website at no cost. Class counsel — the attorneys who negotiated the settlement — already represent all qualifying class members automatically, and they charge you nothing directly.

Is this settlement legitimate? 

Yes. This settlement is part of a federal court case (Case No. 1:19-md-02875) in the U.S. District Court for the District of New Jersey. The official claim website is sartanmedicationsettlement.com and the settlement administrator is Postlethwaite & Netterville. Do not file through any third-party or unofficial website.

When will I receive my payment?

 The Final Approval Hearing is scheduled for June 30, 2026. If the court grants final approval that day, payments will go out sometime after that date. Settlement payment timelines typically run several months after final approval, depending on whether any appeals are filed.

What if I missed the claim deadline?

 If you do not file by June 2, 2026, you will receive no payment and still lose your right to sue Aurobindo separately for these claims. Courts rarely reopen claim periods. Your only other option would have been to opt out before the June 2 deadline — which preserves your right to sue independently.

Will this settlement payment affect my taxes?

 It may. Payments that compensate you for money you spent on a product — rather than for a physical injury — are generally treated as taxable income by the IRS. Consult a tax professional about how to report any settlement payment you receive.

How do I know if my specific medication qualifies? 

Check the NDC code printed on your prescription bottle or ask your pharmacy for records. The qualifying NDC codes are listed in the “Who Can File a Claim” section above. You can also call the settlement administrator at 1-866-875-9644 or email [email protected] for help.

What is NDEA and why does it matter?

 NDEA stands for N-Nitrosodiethylamine, a chemical compound the World Health Organization classifies as a probable human carcinogen. It should not be present in medication at detectable levels. The FDA initiated recalls of several sartan-type blood pressure drugs — including irbesartan — after contamination was discovered in manufacturing processes starting around 2018.

Can I still opt out and file my own lawsuit? 

Yes, but only if you submit a written opt-out request postmarked by June 2, 2026. Opting out means you give up your right to any payment from this settlement but keep the right to pursue your own legal claims against Aurobindo. Given the cost of individual litigation versus a standard settlement payout, opting out makes sense only if you believe you suffered significant personal damages beyond economic loss.

Consumers who want to understand more about how drug contamination cases typically unfold can find related background in this overview of open class action settlements you can claim in April 2026, which covers how settlement funds work and what to expect after you file. If you are also concerned about medication safety more broadly, our coverage of FDA drug recalls and contamination lawsuits explains what contamination standards exist and what your rights are when a product fails to meet them.

Sources & References

1. Official Settlement Website: sartanmedicationsettlement.com
2. Official Claim Portal: sartanmedicationsettlement.pnclassaction.com
3. Court Case Docket: In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation, Case No. 1:19-md-02875-RBK-SAK, U.S. District Court for the District of New Jersey
4. Settlement FAQ (Official): sartanmedicationsettlement.com/faqs/#Aurobindo

Last Updated: April 7, 2026

Disclaimer: This article is for informational purposes only and does not constitute legal advice. Legal claims and outcomes depend on specific facts and applicable law. For advice regarding a particular situation, consult a qualified attorney.